On March 16, 2023, the U.S Food and Drug Administration (FDA) approved dabrafenib with trametinib for pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.
For more information read the FDA announcement and the Novartis announcement.
Posted 3/20/2023
The 2026 NCCN Fall Policy Summit explored the current state of cancer screening and prevention services in the US, barriers that still drive disparities in screening uptake, and strategies to shift the paradigm of preventive cancer care.
